The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy

  • Kim, Hyunseong (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Gihyun (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Sohn, Sung-Hwa (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Lee, Chanju (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Kwak, Jung Won (Department of Physiology, College of Korean Medicine, Kyung Hee University) ;
  • Bae, Hyunsu (Department of Physiology, College of Korean Medicine, Kyung Hee University)
  • Received : 2015.11.07
  • Accepted : 2016.03.14
  • Published : 2016.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

$Foxp3^+$ $CD25^+CD4^+$ regulatory T (Treg) cells are crucial for the maintenance of immunological self-tolerance and are abundant in tumors. Most of these cells are chemo-attracted to tumor tissues and suppress anti-tumor responses inside the tumor. Currently, several cancer immunotherapies targeting Treg cells are being clinically tested. Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment. While cisplatin is a powerful drug for the treatment of multiple cancers, there are obstacles that limit its use, such as renal dysfunction and the development of cisplatin-resistant cancer cells after its use. To minimize these barriers, combinatorial therapies of cisplatin with other drugs have been developed and have proven to be more effective to treat cancer. In the present study, we evaluated the effect of the combination therapy using methyl gallate with cisplatin in EL4 murine lymphoma bearing C57BL/6 mice. The combinatorial therapy of methyl gallate and cisplatin showed stronger anti-cancer effects than methyl gallate or cisplatin as single treatments. In Treg cell-depleted mice, however, the effect of methyl gallate vanished. It was found that methyl gallate treatment inhibited Treg cell migration into the tumor regardless of cisplatin treatment. Additionally, in both the normal and cisplatin-treated tumor-bearing mice, there was no renal toxicity attributed to methyl gallate treatment. These findings suggest that methyl gallate treatment could be useful as an adjuvant method accompanied with cisplatin therapy.

Keywords

References

  1. Campbell DJ. Control of regulatory T cell migration, function, and homeostasis. J Immunol. 2015;195:2507-2513. https://doi.org/10.4049/jimmunol.1500801
  2. Lee H, Lee H, Kwon Y, Lee JH, Kim J, Shin MK, Kim SH, Bae H. Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells. J Immunol. 2010;185:6698-6705. https://doi.org/10.4049/jimmunol.1001373
  3. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1-7. https://doi.org/10.1016/j.coi.2013.12.005
  4. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol. 2013;4:190.
  5. Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237:219-227. https://doi.org/10.1016/j.toxlet.2015.06.012
  6. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378. https://doi.org/10.1016/j.ejphar.2014.07.025
  7. Ganesh S, Iyer AK, Weiler J, Morrissey DV, Amiji MM. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids. 2013;2:e110. https://doi.org/10.1038/mtna.2013.29
  8. Kim YH, Choi BK, Kim KH, Kang SW, Kwon BS. Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res. 2008;68:7264-7269. https://doi.org/10.1158/0008-5472.CAN-08-1365
  9. Lyass O, Hubert A, Gabizon AA. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res. 2001;7:3040-3046.
  10. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117. https://doi.org/10.1146/annurev.immunol.021908.132544
  11. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759-767.
  12. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805-812. https://doi.org/10.1038/nrc3153
  13. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307. https://doi.org/10.1038/nri1806
  14. Son CH, Bae JH, Shin DY, Lee HR, Jo WS, Yang K, Park YS. Combination effect of regulatory T-cell depletion and ionizing radiation in mouse models of lung and colon cancer. Int J Radiat Oncol Biol Phys. 2015;92: 390-398. https://doi.org/10.1016/j.ijrobp.2015.01.011
  15. Chen L, Zhou S, Qin J, Hu H, Ma H, Liu B, Wang X, Ma J, Ye S, Zhong C, Zhou G, Liang C. Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Mol Cancer. 2013;12:153. https://doi.org/10.1186/1476-4598-12-153
  16. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, Miller DM, Chesney J. Transient T cell depletion causes regression of melanoma metastases. J Transl Med. 2008;6:12. https://doi.org/10.1186/1479-5876-6-12
  17. Khan S, Burt DJ, Ralph C, Thistlethwaite FC, Hawkins RE, Elkord E. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol. 2011;138:85-96. https://doi.org/10.1016/j.clim.2010.09.011
  18. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616-622. https://doi.org/10.1200/JCO.2012.44.6112
  19. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7:880-887. https://doi.org/10.1038/nrc2250
  20. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-344. https://doi.org/10.1002/eji.200324181
  21. Lake RA, Robinson BW. Immunotherapy and chemotherapy--a practical partnership. Nat Rev Cancer. 2005;5:397-405. https://doi.org/10.1038/nrc1613
  22. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63:4490-4496.
  23. van der Most RG, Robinson BW, Lake RA. Combining immunotherapy with chemotherapy to treat cancer. Discov Med. 2005;5:265-270.
  24. Ding Y, Xu J, Bromberg JS. Regulatory T cell migration during an immune response. Trends Immunol. 2012;33:174-180. https://doi.org/10.1016/j.it.2012.01.002
  25. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. Blood. 2006;108:426-431. https://doi.org/10.1182/blood-2006-01-0177
  26. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949. https://doi.org/10.1038/nm1093
  27. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006;66:5716-5722. https://doi.org/10.1158/0008-5472.CAN-06-0261
  28. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009; 182:1746-1755. https://doi.org/10.4049/jimmunol.182.3.1746
  29. Lizarraga D, Tourino S, Reyes-Zurita FJ, de Kok TM, van Delft JH, Maas LM, Briede JJ, Centelles JJ, Torres JL, Cascante M. Witch hazel (Hamamelis virginiana) fractions and the importance of gallate moieties--electron transfer capacities in their antitumoral properties. J Agric Food Chem. 2008;56:11675-11682. https://doi.org/10.1021/jf802345x
  30. Da Silva SL, Chaar Jda S, Yano T. Chemotherapeutic potential of two gallic acid derivative compounds from leaves of Casearia sylvestris Sw (Flacourtiaceae). Eur J Pharmacol. 2009;608:76-83. https://doi.org/10.1016/j.ejphar.2009.02.004
  31. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475:226-230. https://doi.org/10.1038/nature10169
  32. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25: 911-920. https://doi.org/10.1038/nbt1323
  33. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409-421. https://doi.org/10.1016/j.ccr.2004.08.031
  34. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19-25. https://doi.org/10.1016/j.it.2010.10.002
  35. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-174. https://doi.org/10.1038/nri2506
  36. Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728-5739. https://doi.org/10.1158/0008-5472.CAN-09-4672

Cited by

  1. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy vol.9, pp.11, 2017, https://doi.org/10.2217/imt-2017-0052
  2. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer vol.19, pp.8, 2016, https://doi.org/10.1080/15384047.2018.1450116
  3. Antineoplastic Activity of Rhus trilobata Nutt. (Anacardiaceae) against Ovarian Cancer and Identification of Active Metabolites in This Pathology vol.10, pp.10, 2021, https://doi.org/10.3390/plants10102074
  4. Role of Sumac (Rhus coriaria L.) in the management of metabolic syndrome and related disorders: Focus on NAFLD-atherosclerosis interplay vol.87, pp.None, 2016, https://doi.org/10.1016/j.jff.2021.104811